Reprogramming of basic metabolic pathways in microbial sepsis : therapeutic targets at last? by Van Wyngene, Lise et al.
Review
Reprogramming of basic metabolic pathways in
microbial sepsis: therapeutic targets at last?
Lise Van Wyngene1,2,† , Jolien Vandewalle1,2,† & Claude Libert1,2,*
Abstract
Sepsis is a highly lethal and urgent unmet medical need. It is the
result of a complex interplay of several pathways, including
inflammation, immune activation, hypoxia, and metabolic repro-
gramming. Specifically, the regulation and the impact of the latter
have become better understood in which the highly catabolic
status during sepsis and its similarity with starvation responses
appear to be essential in the poor prognosis in sepsis. It seems
logical that new interventions based on the recognition of new
therapeutic targets in the key metabolic pathways should be
developed and may have a good chance to penetrate to the
bedside. In this review, we concentrate on the pathological
changes in metabolism, observed during sepsis, and the presumed
underlying mechanisms, with a focus on the level of the organism
and the interplay between different organ systems.
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Introduction: sepsis pathophysiology
Sepsis is a life-threatening condition resulting from a dysregulated
response to infection, with a global burden of at least 19 million
cases annually (Singer et al, 2016). Classically, the acute phase of
sepsis is characterized by an initial strong pro-inflammatory and
innate immune status aimed at eliminating the pathogen. During the
later phase of sepsis, the immune system shifts toward an anti-
inflammatory, immune-suppressive status, resulting in diminished
inflammation, and initiation of tissue repair. Based on these
insights, many immunomodulatory therapies have been tested in
clinical trials in sepsis over the last decades, but no actual novel
therapy based on inflammatory or immune pathways has demon-
strated survival benefit. The only agent that has gained regulatory
approval was activated protein C, but this was later withdrawn from
the market due to safety and efficacy concerns (Ranieri et al, 2012).
Current management of sepsis is supportive rather than curative
and is aimed at eradication of the infection, fluid resuscitation to
maintain organ perfusion, vasopressor administration to maintain
an adequate blood pressure and mechanical support of failing
organs. Even in the face of improved technical advances, mortality
rates of 20–25% are commonly reported (Marshall, 2014). Increas-
ing rates of antimicrobial resistance and aging of the human popula-
tion add to the problem and underscore the need for innovative
therapeutic strategies.
One of the explanations why so many clinical trials have been
disappointing is that sepsis has been considered too much as an
inflammatory disease, while recent research suggests an important
contribution of coagulation, complement activation, microbiome
composition, thermoregulation, circadian rhythm, and metabolism
(Cohen et al, 2015). Indeed, the pathogenesis of sepsis is clearly
influenced by profound changes in metabolic homeostasis. Typical
features of sepsis, such as high fever, tachycardia, tachypnea,
inflammation, immune activation, phagocytosis, and acute phase
reactant production, all require supra-physiological energy supplies.
However, despite their increased nutritional requirements, patients
are often unwilling or unable to eat, which creates a problem of
energy deficit. Also, one recurrent feature in sepsis is a clear prob-
lem of mitochondrial respiration (Protti et al, 2007). Biopsies taken
from skeletal muscle from deceased sepsis patients found a strong
decrease in ATP/ADP ratio (Lee & Hu¨ttemann, 2014).
Similarly, in mice and rats, sepsis led to decreased ATP levels
in skeletal muscle and liver (Lee & Hu¨ttemann, 2014). The imme-
diate result is a high catabolic state leading to the breakdown of
carbohydrates, lipid, and protein reserves (Englert & Rogers,
2016). Interestingly, a large proteomic and metabolic screen on
plasma of sepsis patients identified glucose metabolism and fatty
acid beta-oxidation pathways as being significantly different
between sepsis survivors and non-survivors (Langley et al, 2013).
In human patients, hyperglycemia is very often observed and
occasionally hypoglycemia occurs. A clear increase in L-lactate is
usually seen directly related to poor outcome, besides signs of
poor fatty acid oxidation and amino acid catabolism. It is believed
that short-term and mild changes in metabolism can positively
modulate immune responses to eliminate pathogens and to
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protect the host via disease tolerance, that is, a defense strategy
that limits the pathologic outcome of infections without interfering
directly with the hosts pathogen load (Soares et al, 2014). Uncon-
trolled, severe disturbances of metabolic homeostasis are however
detrimental (Balmer & Hess, 2017). Thus, changes in metabolism
during sepsis can well be the master regulator pathways that aim
to provide energy to overcome the critical situation, but at the
same time save energy because of poor nutritional input. How
the septic organism copes with this schism, and whether these
insights can lead to new therapeutic options, is reviewed in this
paper.
Sepsis and mitochondrial metabolism
A recurrent finding in sepsis is the obvious problem with mitochon-
drial metabolism (Park & Zmijewski, 2017). Even in septic
conditions, glycolysis appears to be perfectly ongoing and pyruvate
is abundantly generated in the cytoplasm of cells. Under well-
oxygenated conditions, pyruvate enters the mitochondria via a
heterodimeric mitochondrial pyruvate carrier protein (MPC)
complex. We are not aware of studies reporting a reduced expres-
sion or function of MPC in sepsis. In contrast, the enzyme complex
responsible for the next necessary step of pyruvate breakdown is
heavily compromised in sepsis: the transformation of pyruvate into
acetyl-CoA and CO2. The multiprotein enzyme pyruvate dehydroge-
nase complex (PDC) is a big, strongly conserved complex that is
tightly regulated in activity and is an important sensor of oxygen
and a regulator of TCA activity. In sepsis, PDC activity is clearly
reduced (Vary, 1996; Nuzzo et al, 2015) and several explanations
have been provided. PDC needs a co-factor, thiamin (a.k.a. vitamin
B1), and this molecule has been found to be reduced in sepsis
samples, but clinical trials using thiamin were rather disappointing
(Leite & de Lima, 2016). More likely, PDC loses activity due to
Glossary
Aerobic glycolysis
A.k.a. Warburg effect: first described by Otto Warburg as a
characteristic of cancer cells. Warburg observed that cancer cells
generate energy (ATP) through high rates of glycolysis, rather than
through oxidative phosphorylation.
Anorexia
Reduced food intake.
Beta-oxidation
Metabolic pathway in which fatty acids are metabolized to generate
energy.
Catabolism
Process that breaks down molecules into smaller units.
Cecal ligation and puncture (CLP) model
One of the most stringent models of sepsis. It involves a combination
of three insults: tissue trauma due to laparotomy, necrosis caused by
ligation of the cecum, and infection due to the leakage of peritoneal
microbial flora into the peritoneum.
Cori cycle
A.k.a. glycose-lactate cycle: metabolic pathway in which lactate
produced by anaerobic glycolysis in the muscles moves to the liver
and is converted to glucose, which in turn is metabolized back to
lactate in the muscles.
Disease tolerance
Defense strategy limiting the pathologic outcome of infections by
preventing tissue damage or ameliorating tissue function without
interfering with host’s pathogen load.
Electron transport chain
A system of molecules that pass electrons from one to another via
redox reactions coupled with the transfer of protons across the inner
membrane of mitochondria, creating a proton gradient that drives
ATP synthesis.
Epigenome
Heritable chemical changes of the genome, such as DNA methylation
or histone modification, that modifies gene expression but does not
change the DNA nucleotide sequence itself.
Free fatty acid
A non-esterified fatty acid, released by the hydrolysis of triglycerides
within adipose tissue. Free fatty acids can be used as an immediate
source of energy by many organs and can be converted by the liver
into ketone bodies.
Glasgow coma scale score
Provides a practical method for assessment of impairment of
conscious level based on eye, verbal, and motor criteria.
Gluconeogenesis
Metabolic process in which glucose is formed from smaller precursors,
such as amino acids and glycerol.
Glycolysis
Generation of ATP through degradation of glucose, usually associated
with anaerobic conditions.
Immunoparalysis
Persistence of a compensatory anti-inflammatory innate immune
response following an insult such as sepsis or trauma.
Ketogenesis
Production of ketone bodies by breaking down fatty acids and
ketogenic amino acids. This process supplies the needed energy of
certain organs, especially the brain.
Lipolysis
The process of breaking down of lipids into fatty acids and glycerol.
Oxidative phosphorylation
A.k.a. mitochondrial respiration: generation of ATP through
the mitochondrial inner membrane via the tricarboxylic acid cycle,
whereby oxygen functions as terminal proton acceptor.
Reactive oxygen species (ROS)
Derivatives of oxygen generated during mitochondrial oxidative
metabolism. A buildup of ROS in cells may cause damage to DNA,
RNA and proteins.
Sepsis
A life-threatening condition that arises when the body’s response to
an infection leads to tissue and organ damage.
Sequential organ failure assessment (SOFA)
Assessment of a patients status, during the stay in an intensive care
unit, used to determine the extent of organ dysfunction. The score is
based on six different scores (respiratory, cardiovascular, hepatic,
coagulation, renal and neurological systems). A higher SOFA score is
associated with an increased risk of mortality.
Starvation
Malnutrition following, for example, anorexia, gastrointestinal disease,
cancer, and coma. The metabolic response to starvation is
mobilization of energy via catabolism of body tissues (muscle, adipose
tissue).
Tricyclic acid cycle (TCA)
A.k.a. Krebs cycle, is the major energy-producing pathway and occurs
in mitochondria. Short carbon chains derived from sugars, fatty acids,
or amino acids are metabolized to yield carbon dioxide, water, and
high-energy phosphate bonds (ATP).
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phosphorylation by a set of kinases known as pyruvate dehydroge-
nase kinase, PDKs. There are four such kinases, PDK1 to PDK4.
These kinases are regulated by transcription [e.g., by transcription
factors such as hypoxia-inducible factor 1a (HIF-1a), glucocorticoid
receptor (GR), peroxisome proliferator-activated receptor (PPAR-a),
and others] as well as by other mechanisms (Jeoung, 2015).
Researchers have also found other kinases that inhibit PDC activity,
notably the mitogen-activated protein kinase (MAPK) kinases (Park
& Jeoung, 2016) and the kinase involved in necroptosis, receptor
interacting protein kinase 1 (RIPK3; Yang et al, 2018). Obviously,
there is a clear point of intersection of different potentially key
pathways in sepsis, namely inflammation, hypoxia, and stress.
Once inactivated, the PDC complex can return to an active status
by means of de-phosphorylating phosphatases. From an evolution-
ary point of view, PDC is closely related to a-ketoglutarate dehy-
drogenase complex, which is similar in structure, also needs
thiamin, and performs de-carboxylation and addition of CoA to a
substrate (forming succinyl CoA from a-ketoglutarate in the TCA
cycle). There are however no reports of changes of this enzyme in
sepsis.
Other problems with mitochondria have been reported in relation
to sepsis. Several groups have demonstrated that mitochondria
display physical damage (Zang et al, 2014). Dysfunction of mito-
chondria in sepsis has been described as being a direct result of
small, reactive molecules, produced in the first wave of inflamma-
tion, for example NO, CO, and reactive oxygen and nitrogen species,
whereby mitochondrial DNA is damaged as well as proteins of the
electron transport chain (ETC.; Svistunenko et al, 2006). The ETC.
multiprotein complexes have also been described as being less
abundant in cells from septic patients due to reduced expression
(Lee & Hu¨ttemann, 2014). The ETC. serves to transport the electrons
generated in the TCA cycle and finally to reduce the terminal
electron acceptor O2 to water, in coordination with flux of protons
from the matrix into the intermembrane space and back to the mito-
chondrial matrix. In sepsis, complex I and complex II of the ETC.
have been found to be less active, but also complex IV has been
claimed as a major mitochondrial target (Hu¨ttemann et al, 2012b).
Phosphorylation of this complex [by inflammatory kinases such as
c-Jun-N-terminal kinase (JNK) that enter mitochondria] is thought
to lead to physical problems with mitochondria, including leakage
of matrix components into the cell, exposing cytochrome C which
initiates apoptosis of the cells (Hu¨ttemann et al, 2012a). This view
is compatible with the observations that in sepsis, mitochondria
are less involved in oxidative phosphorylation and more in the
induction of apoptosis (Lee & Hu¨ttemann, 2014).
Despite the strong evidence pointing toward mitochondrial
dysfunction during sepsis, other studies have shown that mitochon-
drial function in sepsis is highly variable between organs and over
the course of the disease. These statements open the discussion to
whether mitochondrial impairment is the major driver of organ fail-
ure in septic shock and urges the field to investigate this issue in
more detail.
The increased production of lactate in sepsis is thought to be
the result of increased glycolysis activity (aerobic glycolysis a.k.a.
Warburg effect) and increased reduction of pyruvate, and this is
based on several changes, which may be problematic in sepsis.
First, there is the reduction in PDC activity, and other issues with
mitochondria, as just explained. Second, in sepsis there is
cytopathic hypoxia. Several authors have shown that the oxygen
levels in tissues during sepsis are rather normal (Fink, 2015) but
that there is a reduced capacity of the tissues to utilize O2 from the
blood (Suetrong & Walley, 2016). Other authors have demonstrated
that during a decrease in oxygen delivery to cells (oxygen
delivery = cardiac output × O2 carrying capacity of blood), normal
cells will respond with a production of lactate when oxygen deliv-
ery reaches a lower limit of about 400 ml/min. Septic cells will
however respond much more sensitive, that is, from a lower limit
of about 600 ml/min (Suetrong & Walley, 2016). Third: despite
there being no hypoxia senso stricto, septic cells will perform a
hypoxic response and there is transcriptional increase and activa-
tion of HIF1-a (further described below). This transcription factor
will induce several genes, coding for proteins that are involved in
glycolysis, namely hexokinase, phosphofructokinase-1, and most
importantly lactate dehydrogenase A (LDHA; Marı´n-Herna´ndez
et al, 2009), which converts pyruvate into lactate. Lactate is then
pumped into the extracellular space by increased expression of
MCT4 (coded by the SLC16A3 gene). Fourth, lactate is transported
in the blood and, as a reduced metabolite, can be used as an
energy source by different tissues, such as cardiac muscle. Already
four decades ago, it was shown that in sepsis, the oxidation of
lactate to pyruvate is defective, most likely because due to aberra-
tions of two mitochondrial shuttle systems which transport the
protons (derived from the oxidation of lactate) into the mitochon-
dria (Jones, 1974). Fifth, under physiological conditions and during
physical activities, lactate released into the blood will be taken up
by the liver and used as a substrate to form glucose by a process
called gluconeogenesis. This cycle of glucose to lactate catabolism
followed by new glucose production from lactate is called the Cori
cycle, after Gerty and Carl Cori, rewarded by the Noble Award in
1947. As shown by Clemens et al, in a rat sepsis model (the cecal
ligation and puncture (CLP) model; Dejager et al, 2011), this
lactate-based gluconeogenesis in liver is severely reduced (Clemens
et al, 1983). The mechanism behind this defect in gluconeogenesis
is unknown, but could in part be explained by the fact that, the
first step that oxidizes lactate to pyruvate, again requires one of
these defective mitochondrial shuttles. Moreover, even if pyruvate
is formed, it will have to be transformed to phosphoenolpyruvate
(PEP) via a step performed in mitochondria and again involving an
oxaloacetate-malate-oxaloacetate shuttle, leading to oxaloacetate in
the cytoplasm and its de-carboxylation to PEP via the critical
enzyme PEPCK (coded by PCK1). Several studies have shown that
PCK1 expression is significantly decreased in the liver in sepsis
(Deutschman et al, 1993).
In conclusion, based on these mechanisms, in sepsis, there is a
clear increase in production of lactate, and the major pathways to
remove lactate are blocked. Lactate is a typical biomarker of bad
prognosis in sepsis, since lactate levels strongly correlate with
disease severity, morbidity, and mortality in sepsis (Nichol et al,
2010; Rishu et al, 2013). The degree of lactate clearance in a septic
patient, during the first 6 h of sepsis treatment, is highly associated
with survival in sepsis (Nguyen et al, 2004). Lactate may lead to
lactic acidosis (serum pH < 7.35), which results in reduced glucose
uptake by the brain, leading to coma, and induction of heart
arrhythmias and heart failure (Suetrong & Walley, 2016). A low
Glasgow Coma Scale score and cardiovascular failure are both
factors influencing the Sequential [Sepsis-related] Organ Failure
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Assessment (SOFA) score, which is a score reflecting how severely
compromised different organ systems are in sepsis (Singer et al,
2016). Severe lactic acidosis (pH < 7.2) is associated with a mortal-
ity rate of about 50%, and even no surviving patients has been
reported with severe lactic acidosis with a pH under 7.0 (Kimmoun
et al, 2015). Lactate has been reported not only as an important
intermediate in metabolic processes and as a cause of pH decline,
but also as a molecule actively influencing inflammation. For
example, lactate boosts Toll-like receptor-4 (TLR4), that is, the
major receptor of LPS, signaling, and NF-jB-mediated gene tran-
scription (Samuvel et al, 2009) and promotes HMGB1 release (Yang
et al, 2014) in macrophages, suggesting that lactate promotes
inflammation.
The problems with mitochondrial function also impact fatty acid
and protein catabolism, as described further.
Sepsis and carbohydrate metabolism
Hyperglycemia
The pathogenesis of sepsis is associated with a deregulation in
glucose metabolism resulting in a metabolic and energetic failure
(Fig 1). Hyperglycemia is one of the most prevalent metabolic
derangements in sepsis patients, presumably resulting from altered
glycogen metabolism and profound insulin resistance (Englert &
Rogers, 2016). From an evolutionary perspective, hyperglycemia is
thought to be desirable as it provides glucose to cells that do not rely
on insulin for glucose uptake, such as neurons and leukocytes (Marik
& Bellomo, 2013). Redirection of glucose to immune cells allows
meeting their rapid division as well as their bio-energetic demands
during inflammation. Indeed, naı¨ve cells rely mainly on oxidative
phosphorylation and beta-oxidation of free fatty acids as energy
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Figure 1. Impact of sepsis on carbohydrate metabolism.
Naïve immune cells rely on glycolysis and oxidative phosphorylation as the main metabolic pathways to generate ATP. Glycolysis is the catabolic process in which glucose is
converted into pyruvate. Extracellular glucose is imported into cells by GLUT1 (SLC2A1 gene). Subsequent intracellular processing of glucose yields two pyruvate molecules
and two ATP molecules by a series of enzymatic reactions. At sufficient O2 tension, pyruvate is imported in mitochondria and converted into acetyl-coA and enters the
tricarboxylic acid cycle (TCA cycle, a.k.a. Kreb’s cycle), after which each pyruvate yields 17 ATPmolecules by the electron transport chain (ETC) and oxidative phosphorylation.
Upon activation of immune cells, the glycolysis pathway is upregulated under the control of HIF-1a. Themetabolic pathway shifts from oxidative phosphorylation to aerobic
glycolysis, also referred to as the Warburg effect, to meet the increased energy demand in activated immune cells. Despite the presence of abundant O2 in the environment,
glucose is then directly metabolized into lactate. Although energetically less favorable (glycolysis generates 2 molecules of ATP out of 1 molecule glucose, whereas oxidative
phosphorylation provides 36 ATP molecules), aerobic glycolysis allows higher velocity of glycolysis and thus faster ATP production, as well as provides important precursors
for the synthesis of lipids, amino acids, and nucleotides required for proliferation. Interfering with aerobic glycolysis in immune cells has been shown to undermine their anti-
infectious activities, highlighting the importance of this altered metabolism in activated immune cells.
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sources, whereas activated immune cells rely mainly on aerobic
glycolysis, also referred to as the Warburg effect (Cheng et al, 2016;
Fig 2). Although energetically less favorable in terms of ATP produc-
tion, aerobic glycolysis is adopted by activated immune cells because
it provides biosynthetic intermediates that are essential for the
synthesis of nucleotides, lipids, and amino acids. These are important
to support proliferation and the synthesis of inflammatory molecules.
For instance, glucose 6-phosphate (G6P), generated by the first step
in glycolysis, can feed into the pentose phosphate pathway to support
nucleotide synthesis. This pathway also generates NADPH which is
essential for lipid synthesis. Furthermore, an adequate immune
response requires rapid energy production and aerobic glycolysis
provides ATP swiftly. Oxidative phosphorylation requires mitochon-
drial biogenesis, which is a complex and slow process, whereas
glycolysis could be induced rapidly by inducing glycolytic enzymes
(Loftus & Finlay, 2016; O’Neill et al, 2016). Conversion of glucose
into lactate allows high rates of glycolysis providing rapid ATP
production and lactate can also be used as a highly reduced (H-rich)
tri-carbon fuel. Finally, because of suboptimal ETC. function, mito-
chondrial TCA-mediated respiration in sepsis leads to the production
of dangerous reactive oxygen species (ROS; Arulkumaran et al,
2016), a process which can also be prevented by switching to glycoly-
sis, which generates ATP without ROS production and this might be a
form of damage control.
Glycolysis has been shown to be crucial for a number of immune
cell functions in several activated immune cells in order to meet
their increased energy needs. For example, glycolysis is specifically
required for phagocytosis and cytokine production in pro-inflamma-
tory (M1) macrophages (Yang et al, 2014; Jha et al, 2015), for
cytokine production in T cells (Chang et al, 2013), for antibody
production in B cells (Caro-Maldonado et al, 2014) and for antigen
presentation in dendritic cells (Everts et al, 2012, 2014). The
increased serum lactate levels during sepsis hence could also origi-
nate from activated immune cells undergoing aerobic glycolysis
(Cheng et al, 2014b).
From the above-mentioned studies, it is clear that there is a close
link between metabolism and inflammatory responses. If it is true
that high lactate levels would be derived from white blood cells,
therapeutic modulation of leukocyte metabolism could potentially
represent a novel therapeutic approach in sepsis. Appropriate
inflammatory responses are essential for pathogen elimination, but
excessive inflammation may result in overstimulation, organ
damage, and even death.
One key mediator of aerobic glycolysis is the transcription factor
HIF-1a (Corcoran & O’Neill, 2016). HIF-1a regulates the expression of
aerobic glycolysis-related genes (such as glucose transporter 1
(GLUT1, encoded by SLC2A1), LDHA, and PDK4, as well as
inflammatory genes, notably interleukin-1b (IL1B gene; Corcoran &
O’Neill, 2016) and inducible NO synthase (NOS2 gene). Under
hypoxic conditions, but also by stimulation by bacterial products
[e.g., lipopolysaccharide, LPS, of Gram-negative bacteria (Nishi et al,
2008)], and pro-inflammatory cytokines [e.g., TNF (Regueira et al,
2009)] under normoxic conditions, HIF-1a protein is stabilized and
accumulates in cells. Conditional knock-out of HIF-1a in myeloid cells
was found to decrease inflammatory cytokine production and to
protect animals against endotoxemia, an experimental model of
sepsis (Peyssonnaux et al, 2007). Functional work with HIF-1a KO
mice in real bacterial sepsis models has not been performed so far.
Another important mediator in aerobic glycolysis is pyruvate
kinase isoenzyme M2 (PKM2), which acts as a co-activator for HIF-
1a and is also involved in a classical metabolic step, namely the last
step of glycolysis, that is, the de-phosphorylation of phospho-
enolpyruvate to pyruvate. It is activated in hypoxia but also induced
after LPS stimulation. Knockdown of PKM2 decreases lactate
production and cytokine release both in vitro and in vivo leading to
protection of mice from lethal endotoxemia and sepsis (Yang et al,
2014). Impairing the transcriptional activity of the PKM2/HIF-1a
complex by use of small molecules polarizes M1 macrophages into
an M2 phenotype, leading to reduced IL-1b and induced IL-10
production. However, counteracting the inflammatory response
with these small molecules in an Salmonella typhimurium model
interferes with the bacterial killing capacity leading to increased
bacterial dissemination (Palsson-Mcdermott et al, 2015).
Also mammalian target of rapamycin (mTOR) has been
described as an important regulator of HIF-1a activity. mTOR
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Figure 2. The pathogenesis of sepsis is associated with a deregulation in
glucose metabolism.
Both high and low glucose levels correlate with sepsis severity. Initially, a
hyperglycemic response is observed in both animal models and in human
patients, presumably resulting from insulin resistance and altered glycogen
metabolism. This allows redirection of glucose to immune cells supporting
aerobic glycolysis and thus immune function, and also leads to lactate
production. In later stages, hypoglycemia could be observed as a consequence of
several factors. In contrast to animal models, hypoglycemia is less frequently
observed in human patients.
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activity is induced by hypoxia, growth factors, and a number of
ligand-receptor systems, and leads to increased translation of a
number of key mRNAs, including HIF-1a mRNA (Cheng et al,
2014a). mTOR is negatively involved in the function of regulatory
T cells (Treg), because increased glycolysis in peripheral Treg cells
may impair their lineage and survival integrity (Wei et al, 2016).
Inhibition of the mTOR pathway by metformin decreases cytokine
production in a Candida albicans infection model, leading to
increased fungal outgrowth and decreased survival of mice in this
infection model (Cheng et al, 2016).
We thus see here a number of examples that show that inhibition
of cytokine release, via manipulation of metabolic pathways, undermi-
nes the activities of essential immune cells, which blunts the proper
clearage of the infection. So, it is important to limit exaggerated
immune and inflammatory responses during sepsis, while ensuring a
minimal amount of immunity for the clearing of the ongoing infection.
Besides targeting HIF-1a, PKM2, mTOR, or other similar central
coordinating factors, another strategy to target glycolysis is with
2-deoxy-D-glucose (2-DG). Hexokinase (HK) is the initial and rate-
limiting enzyme in glycolysis). HK converts 2-DG to phosphorylated
2-DG (2-DG-6p), which inhibits HK activity thereby inhibiting glycol-
ysis. In vitro, 2-DG suppresses HIF-1a and its targets IL-1b and
HMGB1 in activated macrophages (Tannahill et al, 2013; Yang et al,
2014). In T cells, blocking glycolysis with 2-DG leads to a differentia-
tion of Th17 cells into Treg cells (Shi et al, 2011). In vivo, 2-DG
significantly improves survival in both the LPS (Wang et al, 2016)
and CLP (Zheng et al, 2017) model of sepsis by downregulating
lactate and inflammatory cytokine production. In contrast, 2-DG
conferred no protection in a poly(I:C)—induced systemic inflamma-
tion model (Wang et al, 2016).
Patients that survive the acute hyperinflammatory phase of sepsis
remain at an increased risk for secondary infections, and conse-
quently late stage mortality (Wang et al, 2014). Understanding the
mechanisms that underlie immunoparalysis in sepsis is also crucial
for the identification of novel therapeutic approaches in sepsis.
Immunotolerant leukocytes show broad metabolic defects at the level
of both glycolysis and oxidative metabolism. One group has demon-
strated that restoring the ability of immunotolerant leukocytes to
mount a glycolytic response by treatment with IFN-c leads to an
increased cytokine production and might represent a promising novel
therapeutic approach to revert the immunotolerant state of sepsis
(Cheng et al, 2016). A phase III clinical trial evaluating the effect of
IFN-c on sepsis-induced immunoparalysis (NCT01649921) has been
conducted, but results have not yet been reported. The same group
showed that aerobic glycolysis is also important for trained immunity,
that is, the memory characteristics of the innate immune system.
Pretreatment of mice with the b-glucan component of C. albicans
induces a non-specific protection against infections, such as with
Staphylococcus aureus. However, mice with a myeloid-cell-specific
defect in HIF-1a are unable to mount a trained immunity against
S. aureus and succumb to the infection (Cheng et al, 2014a).
Hypoglycemia
In later stages, sepsis can also be characterized by hypoglycemia. In
preclinical animal models, for example, mouse endotoxemia or
mouse CLP, hypoglycemia is inevitable and linked with severity
(Drechsler et al, 2015). Also in human patients, spontaneous
hypoglycemia can be observed (Miller et al, 1980; Romijn et al,
1990; Rattarasarn, 1997; Singanayagam et al, 2009) but occurs less
frequently. The fact that hypoglycemia occurs in mouse sepsis
models and is less observed in human sepsis, may be based on (i)
the relatively big surface to volume ratio in mice compared to
humans, by which mice therefore lose heat much faster than men,
and have to compensate this by a higher heart rate and metabolic
turnover, and (ii) because humans are fed with glucose and other
nutrients in the ICU. The mechanisms leading to hypoglycemia are
not well understood. Depleted glycogen storages, increased periph-
eral usage of glucose, anorexia (Wang et al, 2016; Weis et al, 2017),
and/or decreased gluconeogenesis (Dendoncker & Libert, 2017;
Weis et al, 2017) may all be contributing factors.
Acute infections are associated with the development of anorexia,
that is, an aspect of sickness behavior characterized by reduced food
intake and thereby reduced blood glucose levels. It has recently been
shown that this fasting metabolic state is crucial for survival of bacte-
rial sepsis, whereas it may be detrimental for viral inflammation
(Wang et al, 2016). Prolonged fasting results in hypoglycemia
accompanied by lipolysis and ketogenesis, that is, the generation of
ketone bodies. Ketone bodies [there are three common such ketone
bodies, namely acetone, acetoacetate, and b-hydroxybutyrate (BHB)]
have been shown to confer resistance to reactive oxygen species
(ROS)-mediated damage. By supplementing glucose during bacterial
sepsis, ketogenesis is suppressed, leading to inhibition of these
ketone body-mediated ROS adaptation pathways. This mechanism
seems to be required for preventing ROS-induced neuronal damage
in bacterial inflammation, whereas it is dispensable in case of viral
inflammation (Wang et al, 2016). Next to ketone bodies, alternative
pathways that control ROS production, the release of ROS into the
cytoplasm, the interaction of ROS with specific substrates such as
kinases, and the detoxification of ROS can play important roles
during sepsis pathophysiology, as was recently reviewed comprehen-
sively by Kozlov et al (2017). In contrast, the study of Weis et al has
shown that liver glucose production in response to bacterial infection
is essential to establish disease tolerance. The authors suggest that
liver gluconeogenesis is required to prevent lethal hypoglycemia in
response to acute infection. According to this study, gluconeogenesis
in the liver is hampered during sepsis due to iron-driven oxidative
inhibition of glucose-6-phosphatase (Weis et al, 2017). Presumably,
anorexia is important to establish disease tolerance to systemic
bacterial infections, and this could explain why this behavior is
conserved from humans to insects (Wang et al, 2016). However, the
blood glucose levels need to be maintained within a physiological
range compatible with host survival and might thus not fall below a
certain threshold (Chervonsky, 2017).
Control of glucose levels in sepsis: controversy
Both high (Gunst & Van den Berghe, 2016) and low glucose
(Singanayagam et al, 2009; Krinsley et al, 2011) levels correlate
with poor outcome in sepsis patients. Severe hyperglycemia has
been shown to induce, that is, mitochondrial damage, endothelial
dysfunction, acute kidney injury, liver dysfunction, muscle weak-
ness, and long-term neurocognitive impairment (Gunst & Van den
Berghe, 2016). Severe hypoglycemia, in contrast, has been demon-
strated to induce, for example, sudden cardiac arrest by inducing
ischemic or depolarization/repolarization changes, neurocognitive
impairment (acute coma), endothelial dysfunction, blood coagula-
tion abnormalities, and increased inflammation (Kalra et al, 2013).
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Three pioneer randomized controlled trials on tight glucose
control found that control of glucose levels with insulin improved
the outcome in sepsis patients as compared to control groups (Van
den Berghe et al, 2001, 2006; Vlasselaers et al, 2009). These studies
have led to a change in standard of care and have implemented
control of glycemic levels to prevent excessive hyperglycemia
(Gunst & Van den Berghe, 2016). However, there have been some
concerns about the risk of developing severe hypoglycemia, the
difficulty of achieving normoglycemia in ICU patients, and the
contradicting results of some follow-up studies (Marik, 2016).
Therefore, a new clinical trial to test the value of tight glycemic
control was conducted, namely the Normoglycemia in Intensive
Care Evaluation–Survival Using Glucose Algorithm Regulation
(NICE-SUGAR) trial (Riske et al, 2009). The NICE-SUGAR trial
found that intensive glucose control in fact increased mortality,
suggesting that slightly elevated glucose levels are rather beneficial
and that glycemic control in ICU patients should be abandoned. It
should be noted that in the NICE-SUGAR study, the control group
was also treated with insulin to keep glycemic levels between 140
and 180 mg/dl, instead of the uncontrolled hyperglycemia (up to
215 mg/dl) in the first studies (Gunst & Van den Berghe, 2016). It
thus remains unclear how to manage glucose levels in ICU patients,
but it seems that safe, effective glucose control may be advanta-
geous over tight glycemic control.
Sepsis and fatty acid metabolism
Substantial activation of the immune system during sepsis,
combined with the inability of most patients to keep up adequate
nutrition, induces a starvation response in which next to glycolysis,
energy needs are also supplied by lipid mobilization and oxidation
(Jorgen et al, 1982; Wolowczuk et al, 2008). The storage of lipids as
triglycerides (TGs) in adipose tissue comprises the bodies’ largest
endogenous energy supply, allowing the release of fatty acids to
become crucial during states of acutely increased energy needs
(Cahill, 1970; Rittig et al, 2016). When energy demands are
elevated, the body responds by upregulating lipolysis in adipose
tissue, converting TGs into glycerol and free fatty acids (FFAs),
which are subsequently released into the bloodstream (Cahill,
1970). FFAs can be taken up by peripheral organs and converted
into energy by means of the b-oxidation pathway followed by the
TCA cycle (Fig 3). The average fat storage in a young human adult
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Figure 3. An overview of lipolysis and lipid oxidation in healthy
conditions.
(A) Lipolysis is the hydrolytic conversion of triglycerides (TG) into glycerol and
free fatty acids (FFAs) and is most abundant in white and brown adipose tissue.
This process is tightly regulated by glucagon, (nor)epinephrine, and other
hormones, but also by pro-inflammatory cytokines. Hydrolysis of the ester bonds
between long-chain fatty acids and the glycerol backbone is executed by lipases.
Up to now, three enzymes have been implicated in performing the complete
hydrolysis of TG into FFAs and glycerol: adipose triglyceride lipase (ATGL),
hormone sensitive lipase (HSL), and monoglyceride lipase (MGL). The FFAs are
released into the blood stream and can be taken up by peripheral organs to
produce energy via mitochondrial b-oxidation. (B) Fatty acid b-oxidation is a
multistep process breaking down fatty acids in the mitochondria of the cell to
produce acetyl-CoA, which can be used by the tricarboxylic acid (TCA) cycle to
produce ATP. In brief, FFAs are transported across the cell membrane by
members of the FATP transporter family. Once inside the cytosol, the FFA is
coupled to coenzyme A (CoA) by acyl-CoA synthetase (ACS) and shuttled across
the inner mitochondrial membrane by carnitine palmitoyltransferase II (CPT2)
and the carnitine acyltransferase (CAT) after being coupled to carnitine by
carnitine palmitoyltransferase I (CPT1). In the mitochondrial matrix, b-oxidation
is conducted by cleaving two carbon molecules in every oxidation cycle to form
acetyl-CoA. The cycle is repeated until the complete fatty acid has been reduced
to acetyl-CoA, which is subsequently enters the TCA cycle.
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is 10–20 kg, the variation depending on gender, age, and fitness.
The human glycogen reserve, in contrast, consists only of approxi-
mately 400 g, of which 300 g is largely unavailable and sealed
within the skeletal muscles, reinforcing the importance of fat as
potential energy storage (Sloan et al, 1973).
Lipolysis
Next to a deregulated glucose metabolism, the pathogenesis of
sepsis is also known to influence fatty acid metabolism. Decades
ago, it has already been described that lipolysis is upregulated in
white adipose tissue (WAT) during the early phase of endotoxemia
and sepsis (Forse et al, 1987), a finding that was more recently con-
firmed by several other studies (Wellhoener et al, 2011; Ilias et al,
2014; Rittig et al, 2016). Consequently, plasma TGs and FFA levels
have been found to be increased up to 4-fold in septic patients
compared to healthy individuals (Scholl et al, 1984; Lanza-Jacoby &
Tabares, 1990; Nogueira et al, 2008). The molecular mechanisms
behind this upregulation of lipolysis have hardly been addressed.
One study showed that LPS infusion in human subjects led to an
increased phosphorylation of hormone sensitive lipase (HSL) at
Ser650, a modification known to activate the enzyme (Rittig et al,
2016). HSL is one of the best described lipases (encoded by the LIPE
gene) and could, together with the other important enzyme adipose
triglyceride lipase (ATGL, PNPLA2 gene), be involved in the
(patho)physiological lipolysis in white adipose tissue (WAT). Also,
cAMP-dependent protein kinase A (PKA)-dependent phosphoryla-
tion of perilipin 1 (PLIN1) is a decisive step in the activation of lipol-
ysis (Choi et al, 2010) and was found to be elevated after LPS
infusion (Rittig et al, 2016). This suggests that increased PKA activ-
ity might be one of the driving forces behind the increased lipolysis.
Sepsis and endotoxemia are known to cause an acute increase in
stress hormones such as (nor)epinephrine, growth hormone,
glucagon, and cortisol, all of them being typical pro-lipolytic
hormones, which indeed stimulate lipolysis by direct stimulation of
lipolysis in fat cells (Fong et al, 1990; Bloesch et al, 1993). More-
over, insulin resistance is a well-established phenomenon in septic
patients and insulin is a potent inhibitor of lipolysis (Choi et al,
2010). Eventually, all these mechanisms are likely to converge into
an increase in the amounts of FFAs released by lipolysis into the
bloodstream in sepsis.
b-oxidation
Oxidation of FFAs provides a crucial source of energy during condi-
tions of energy needs, starvation, or acute inflammation, including
sepsis (Askanazi et al, 1980; Jorgen et al, 1982). However, the pro-
inflammatory status of this pathology is known to cause a dysregu-
lation in the breakdown of FFAs in a wide variety of organs. A
whole blood genome-wide expression profiling in patients with
septic shock showed that the expression of genes belonging to the
PPAR-a signaling pathway was significantly downregulated in chil-
dren with a more severe disease status (Wong et al, 2009). PPAR-a
is a member of the nuclear receptor family and the most important
transcription factor involved in the transcriptional regulation of
genes coding for proteins involved in the b-oxidation pathway
(Hiukka et al, 2010).
Standage et al (2012) demonstrated more recently that the down-
regulated expression of PPAR-a dependent genes was due to a
reduced PPAR-a expression in whole blood samples, a decrease
which was associated with decreased survival and increased tissue
bacterial load in an experimental polymicrobial septic mouse model.
Furthermore, using bone marrow transplantation experiments, it
was proven that disease severity is primarily determined by organ
tissue PPAR-a expression and not by hematopoietic immune cell
PPAR-a (Standage et al, 2012). Downregulation of PPAR-a expres-
sion levels during infection has also been demonstrated in the liver,
heart, and kidney (Beigneux et al, 2000; Feingold et al, 2008;
Drosatos et al, 2011). In the heart, it was shown that LPS injection
caused a decrease in PPAR-a as well as in PPAR-y co-activator
(PGC)-1a. PGC-1a is a major transcriptional co-factor of PPAR-a,
and its downregulation thus leads to decreased expression of several
PPAR-a target genes and a reduction in the rate of FFA acid b-oxida-
tion in cardiomyocytes. As a consequence of the reduced oxidative
breakdown of FFAs, severe organ damage may occur due to (i)
energy deprivation, (ii) FFA accumulation and lipotoxicity, and (iii)
mitochondrial dysfunction and endoplasmic reticulum (ER) stress
(Fig 4).
Energy deprivation Each of the previously specified organs is highly
metabolically active in order to provide adequate energy to perform
vital homeostatic functions within the body. When increased meta-
bolic needs during acute inflammation are not met, in part due to
mitochondrial dysfunction, life-threatening organ dysfunction can
develop, a recurrent feature of septic shock (Carre´ & Singer, 2008).
It has been hypothesized that restoration of the FFA oxidation in
specific organs could protect against organ dysfunction and poten-
tially lead to increased survival in sepsis. In a zymosan-induced
(sterile) peritonitis model, it was shown that the upregulation of b-
oxidation of FFAs was associated with the resolution of inflamma-
tion (Fujieda et al, 2013). Furthermore, in macrophages and adipo-
cytes, enhanced FFA oxidation led to reduced ER stress and ROS
damage. It was also demonstrated that increased b-oxidation
improved insulin resistance by reducing the triglyceride accumula-
tion and the expression of inflammatory cytokines, two factors that
have been shown to reduce the sensitivity to insulin (Malandrino
et al, 2015). Another study demonstrated that intervention in the
LPS-induced JNK signaling pathway restored PPAR-a expression in
the heart and prevented LPS-induced heart dysfunction (Drosatos
et al, 2011).
Lipotoxicity The combination of increased lipolysis and deficits in
the oxidation of FFAs can lead to the accumulation of these FFAs
and subsequently to lipid-induced toxicity. A proteomic and meta-
bolic screen on plasma of septic patients identified several FFAs to
be significantly upregulated in the blood of non-survivors compared
to survivors (Langley et al, 2013). Lipotoxicity is defined as a meta-
bolic syndrome resulting from the accumulation of lipid intermedi-
ates in non-adipose tissue and can lead to cellular dysfunction and
cell death (Engin, 2017). Under normal conditions, lipids are stored
primarily in adipocytes, with only a minimal presence in other
tissues (Tontonoz & Spiegelman, 2008). When an overload of FFAs
is present due to increased lipolysis and/or decreases in b-oxidation,
lipid deposits can be formed in peripheral organs. Presumably, this
accumulation of fatty acids is not toxic at first; in fact, it can be seen
as some sort of defense mechanism against the excess of circulating
FFAs (Brindley et al, 2010). By taking up a part of the fatty acid
overload, metabolically active organs such as the liver may protect
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more sensitive organs including the lungs from the toxic side effects
of high FFA levels. Clinically, this phenomenon is addressed as
steatosis and has been identified in liver, kidney, and heart after the
onset of endotoxemia and sepsis (Zager et al, 2005; Rossi et al,
2007; Koskinas et al, 2008). When lipids continue to accumulate,
certain lipid metabolites such as diacylglycerol (DAG), ceramide,
and saturated fatty acids reach a critical level that could potentially
be harmful to the tissue cells. It has been accepted that excess of
lipids are ultimately steered toward non-oxidative pathways which
results in the formation of toxic lipid species that cause mitochon-
drial dysfunction (Bugger & Abel, 2008), modify cellular signaling
(Yang & Barouch, 2007) and increase apoptosis (i.e., “lipoapopto-
sis”; Unger & Orci, 2002). More recently, toxic lipid species have
been associated with the induction of ferroptosis, an alternative type
of programmed cell death dependent on iron. The role of ferroptosis
as a cell death mechanism contributing to organ damage in sepsis
has been hardly explored. Nevertheless, ferroptosis has been impli-
cated in acute kidney failure and could be an important alternative
cell death pathway during sepsis (Linkermann et al, 2014; Mu¨ller
et al, 2017; Wenzel et al, 2017). The precise contribution and
impact of each of above-mentioned altered cellular processes have
not been properly delineated and seem to depend on lipid composi-
tion and cell type (Ghosh & Rodrigues, 2006). For a more detailed
discussion on lipotoxicity, we refer to a number of excellent recent
reviews (Wende & Abel, 2010; Ertunc & Hotamisligil, 2016; Engin,
2017).
Mitochondrial dysfunction Mitochondrial dysfunction due to the
fatty acid overload can be caused by the increased production of
ROS (Scho¨nfeld & Wojtczak, 2008), the uncoupling of the oxida-
tive phosphorylation (Rial et al, 2010) and the permeabilization of
the outer mitochondrial membrane (Listenberger & Schaffer,
2002). As stated before, it has been described that systemic
inflammation can affect mitochondria by several mechanisms
such as the generation of excess amounts of nitric oxide, carbon
monoxide and ROS which directly inhibit mitochondrial function
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Figure 4. Lipolysis, fatty acid oxidation, and ketogenesis in sepsis.
Sepsis is associated with the development of an anorectic response since patients are often unwilling or unable to eat. During a normal starvation response and during
sepsis, lipolysis in white and brown adipose tissue is being upregulated by several pro-lipolytic signals. The inhibitory effect on lipolysis of insulin, which is upregulated
in sepsis due to high glucose levels, is however absent due to insulin resistance. Free fatty acids (FFAs) in the blood are upregulated in both conditions and can be taken up by
peripheral organs to produce energy. The increased FFA levels activate and upregulate the expression of PPAR-a, the main transcription factor responsible for the
induction of genes involved in the b-oxidation of fatty acids and the production of ketone bodies (KBs). During sepsis, PPAR-a levels are downregulated and the breakdown of
fatty acids through b-oxidation is compromised, causing FFAs to accumulate in organs such as the liver, heart, and kidney, but also in the blood. Overall, the deficits in
FFA breakdown during sepsis cause a shortage of energy and lipotoxicity and mitochondrial damage due to FFA accumulation. Green represents the normal starvation
response, and red represents the response during sepsis.
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and damage the lipid membrane (Bauer & Pannen, 2009; Larsen
et al, 2012). It seems plausible that the excess amount of fatty
acids might contribute to the development of mitochondrial
dysfunction during sepsis. Lipotoxicity has also been linked to ER
stress and excessive activation of the unfolded protein response
(UPR; Cunha et al, 2008; Baldwin et al, 2012). Many ER stress
responses converge with inflammatory pathways via the activa-
tion of inflammatory kinases such as c-Jun-N-terminal kinase
(JNK) and the I-kappa-B-kinase complex (IKK) and the activation
of the inflammasome (Hu et al, 2006; Nakamura et al, 2010).
Saturated fatty acids, including palmitate, can bind to TRL4 and
induce a MyD88-dependent signaling to eventually activate the
inflammasome and NF-jB signaling pathways (Lee et al, 2001).
Moreover, ceramide, which is produced from long-chain saturated
fatty acids, has been shown to be directly associated with the
induction of insulin resistance and lipoapoptosis (Kanety et al,
1996; Paz et al, 1997; Brookheart et al, 2009).
Therapeutic intervention
It is highly possible that the overload of FFAs, caused by aberrations
in the fatty acid metabolism, contributes to the pathogenesis of
sepsis and that interventions to prevent this accumulation could
potentially ameliorate outcomes in sepsis. To avoid the accumula-
tion and toxic effects of FFAs, one could target several pathways of
the fatty acid metabolism: lipolysis, b-oxidation, or lipogenesis.
Pharmacological inhibition of one of the major lipases, adipose
triglyceride lipase (ATGL), was successful in correcting high-fat
diet-induced insulin resistance and hepatosteatosis in mice (Sch-
weiger et al, 2017). Several potent inhibitors that are directed
toward the other major lipase, HSL, have recently been produced
and might provide an attractive alternative to treat sepsis (Ogiyama
et al, 2017).
Pharmacological prevention of PPAR-a downregulation shows
potential since inhibition of JNK restored PPAR-a protein levels and
was enough to prevent myocardial dysfunction after infection
(Drosatos et al, 2011; Drosatos & Schulze, 2013). Also, interventions
that target co-factors or downstream targets of PPAR-a could possi-
bly contribute to improved oxidation of FFAs and enhanced energy
production. However, extensive research into the mechanisms by
which PPAR-a is downregulated in different organs and other
changes within this metabolic pathway are still needed to provide a
complete view on possible druggable targets.
Another option could be to interfere before PPAR-a is down-
regulated by actively stimulating PPAR-a by the means of
agonists. Indeed, mice on a fenofibrate-loaded diet were found to
show improved survival and repression of the inflammatory
response in infection models (Tancevski et al, 2014). Such a ther-
apy, of course, is purely preventive, and indeed rarely relevant in
a clinical setting. One could argue that increasing the capacity of
WAT to store lipids through adipogenesis by PPAR-c stimulation
might decrease ectopic lipid overload (Gema et al, 2007). The
PPAR-c agonist thiazolidinedione (TZD) was shown to improve
peripheral insulin sensitivity and clearance of TGs in type 2
diabetes (Mayerson et al, 2002), while ameliorating murine
polymicrobial sepsis by reducing the pro-inflammatory signal
transducer and activator of transcription-1 (STAT-1) signaling
pathway (Ferreira et al, 2014). Moreover, several studies reported
a role for PPAR-c in inducing mitochondrial biogenesis (Bolten
et al, 2007; Pardo et al, 2011), a process that has been associated
with survival during early sepsis (Carre´ et al, 2010). Combinato-
rial PPAR-a and PPAR-c stimulation, while actively repressing
lipolysis during the early stages of sepsis could represent an inter-
esting alternative approach. Prospective clinical studies toward
the use of fibrates and TZDs in infectious conditions have been
conducted, but are however still insufficient and should be revis-
ited (Fujita et al, 2006; Boggild et al, 2009).
In conclusion, an activation of lipolysis, associated with a break
on FFA b-oxidation, due to reduced activity of PPAR-a and PGC-1a
and poor function of mitochondria, appears very critical in sepsis
and is open to several key therapeutic interventions. The precise
genes that suffer from reduced transcriptional activity of PPAR-a
and the impact on poor FFA oxidation have hardly been investi-
gated, but the ones that coordinate cellular (CD36) and mitochon-
drial FFA import (SLC25A20, CPT1A, CPT1B), as well as those
involved in the real oxidation pathway, appear logical priorities to
study.
Sepsis and ketogenesis
As discussed above, sepsis leads to a fasting response accompanied
by a pro-lipolytic status with increased lipolysis and ketogenesis
(Wang et al, 2016). Synthesis of the three known ketone bodies is
tightly controlled by PPAR-a and is mainly conducted by mitochon-
dria of liver cells. Next to conferring resistance against ROS-
mediated damage, KBs are also an important source of energy for
brain and skeletal muscle in times of high metabolic activity and
limited glucose availability such as fasting and exercise (Randle
et al, 1964). The production of KBs thus ensures that not all energy
which is contained in FFAs is entirely degraded to acetyl-CoA and
further to CO2 and H2O in the liver TCA cycle, but that other organs,
with much less FFA oxidation capacity can profit from the FFAs
released by lipolysis. Aberrations in ketone metabolism during
sepsis have been described a long time ago by several research
groups (Felig et al, 1971; Flatt & Blackburn, 1974; Wannemacher
et al, 1979). This suggests that the reduced production of KBs could
lead to the increased breakdown of muscle protein, a universally
accepted consequence of sepsis. Moreover, a recent study has
shown that in PPAR-a-deficient mice LPS-induced endotoxemia was
lethal due to the absence of ketogenesis (Wang et al, 2016). Thus
ketogenesis appears essential in the defense to sepsis but may be
inadequately active in sepsis. Also, BHB was shown to block
NLRP3-inflammasome-mediated inflammation not through the clas-
sical starvation-regulated mechanisms such as AMP-activated
protein kinase (AMPK) or ROS, but by mechanically preventing the
K+ efflux and reducing oligomerization of inflammasome compo-
nents (Youm et al, 2015). Furthermore, BHB administration to mice
exposed to high doses of fish oil was protective against acute liver
failure and the lipotoxic effect of peroxidized fatty acids (Pawlak
et al, 2015). In 1994, a study by Beylot et al demonstrated the inhi-
bitory effect of BHB on lipolysis in septic patients, unfortunately,
mortality rates were not considered during this trial (Beylot et al,
1994). Since NLRP3 and high levels of FFAs have been implicated in
the pathogenesis of sepsis (Jin et al, 2017), administration of ketone
bodies might thus be considered as a valuable novel therapeutic
direction.
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Sepsis and amino acid metabolism
In sepsis, a general catabolic status is observed. As we described
above, a starvation-like status leads to breakdown of carbohydrate
and fat reserves, but also protein is degraded in several organs.
Proteolysis, the trimming of proteins into smaller polypeptides and
amino acids (AAs) has been best documented in skeletal muscle.
The signals that lead to extensive muscle wasting or the proteases
involved are poorly described in this condition. Similar to glycogen
breakdown in liver and lipolysis in white adipose tissue, proteolysis
is most likely the result of hormonal regulation, with glucagon and
glucocorticoids being potential candidate regulators, as well as
proteasomal proteases and inflammatory stimuli (Biolo et al, 1997).
The precise reason for the increased proteolysis in sepsis fits into a
general reshuffling of energy-rich molecules, as well as an increased
need of AAs in the liver to sustain the acute phase response (Hassel-
gren et al, 1988). Several amino acids are also known to play an
important role in inflammatory cells. For example, glutamine is an
important precursor for peptide and protein synthesis supporting
cytokine production. Glutamine is also required for purine and
pyrimidine and thus nucleic acid and nucleotide synthesis allowing
proliferation of immune cells. Arginine can be converted into nitric
oxide by nitric oxide synthase, which is then released by M1 macro-
phages.
All AAs are found to be increased in muscle cells, by proteolysis,
and new amino acids seem to be formed due to catabolic chemical
reactions (Su et al, 2015). Also in plasma, most amino acids are
highly altered. Certain amino acids, especially taurine, are found to
play an important role in predicting the severity and outcome in
sepsis (Su et al, 2015). Supplementation of amino acids, such as
glutamine, arginine, and taurine, during sepsis showed positive
outcomes such as reduced length of stay and reduced number of
secondary infections (Arts et al, 2016).
Specifically the branched-chain amino acids (BCAAs), such as
alanine, leucine, and isoleucine, are of interest. These AAs can func-
tion as acceptors of keto-groups from pyruvate and glutamate, lead-
ing to glutamine and alanine. These AAs can enter the blood and
can be used as energy-rich AAs by other organs. Organs that are
classically considered as targets are the kidney, intestine, and liver
(Fig 5). In kidney and intestine, glutamine can be de-aminated to
glutamate, which can enter the TCA cycle via a-ketoglutarate,
potentially leading to the formation of alanine. Under normal condi-
tions, the NH3 that is released during glutamine conversion is
removed via urine or the intestinal lumen. Glutamine metabolism in
the liver is low, especially because the liver has no big capacity to
deal with NH3. Alanine, produced in the muscle, kidney, and intes-
tine is transported to the liver, where it is oxidized and de-aminated
into pyruvate, which can subsequently enter the TCA cycle.
Depending on the degree of hypoxia, pyruvate can be reduced to
lactate or lead to glucose via gluconeogenesis. In septic patients, an
increase in gluconeogenesis due to elevated alanine uptake in liver
would be preferential, but, as stated above, gluconeogenesis is
compromised in sepsis, which might therefore increase alanine
levels in the blood of septic patients as observed by Langley et al
(2013). Increases in ammonia in sepsis blood are observed in case
of severe hepatic failure (Nesseler et al, 2012), a condition that is
estimated to occur in about 20% of septic shock patients. Under
such conditions, liver failure leads to a multitude of problems, such
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Figure 5. Overview of protein catabolism in sepsis.
In sepsis conditions, catabolism of proteins in skeletal muscle is a recurrent feature, but the main regulators are still not identified. Branched-chain amino acids (AAs)
are oxidized to branched-chain keto acids (BCKAs), which can be used in the TCA cycle. Glutamine (Gln) and alanine (Ala) find their way to kidney and intestine and liver. In
the former two, Gln is de-aminated to glutamate (Glu) and ammonia (NH3), which is removed. Glu and pyruvate can yield Ala and a-ketoglutaric acid (aKG),
which can enter the TCA cycle. Ala is mainly used as a gluconeogenic substrate and is transformed to pyruvate, whereby the NH2 group is removed via the urea cycle. During
liver failure, ammonia may leak into the blood, leading to brain damage and coma.
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as bad hepatic capture and transport of bilirubin and bile salts, but
also increased ammonia, resulting from a poor urea cycle. This
latter, in essence a direct result of proteolysis, leads to hepatic
encephalopathy, that is, mental disorientation of patients, a
common finding, and coma (Felipo & Butterworth, 2002).
Epigenetic-metabolic link in sepsis
Epigenetics is defined as a “stably heritable phenotype that does not
involve alterations in the DNA sequence, but chemical changes
within the chromatin” (Berger et al, 2009). These changes include
posttranslational modification of histone proteins (such as acetyla-
tion, methylation, phosphorylation, and ubiquitination), DNA
methylation, and more recently also transient chromatin modifi-
cations and miRNAs (Natoli, 2010). Histone modifications are
completed by specific sets of enzymes adding or removing different
categories of posttranslational modifications, thereby directly modu-
lating the chromatic structure and gene expression (Bannister &
Kouzarides, 2011; Verdin & Ott, 2015). Interestingly, the activity of
these different enzymes is depending on the presence of specific
metabolites, causing chromatin modifications to be directly coupled
to the metabolic state of the cell. It is now generally accepted that
cells evolutionary acquired sensing mechanisms to detect changes
in nutrients and accommodate the transcriptional program via
epigenetic changes (Etchegaray & Mostoslavsky, 2016). On the other
hand, key metabolic-regulating genes are under the control of epige-
netic machineries, creating a feedback loop that could potentially
result into a vicious circle during conditions where metabolic path-
ways are severely altered.
Epigenetic changes during sepsis
Bomsztyk et al (2015) were the first to investigate changes in
histone modifications on a whole-organ level in sepsis-related multi-
ple organs dysfunction syndrome (MODS). They showed that 6 h
after the onset of infection, major epigenetic changes were occurring
in several organs. Moreover, the decrease in gene expression of key
genes involved in endothelial function was associated with a
decrease in permissive histone modifications (acetylation), while
repressive marks (methylation) were unchanged, suggesting that
intervention early into the disease to preserve these permissive
marks could help to keep endothelial integrity intact. A major limita-
tion of this study is the fact that within every organ, many different
cell types are found, each with their own epigenome. More impor-
tantly, during sepsis, there is an extensive infiltration of immune
cells, making a cell-specific approach crucial.
Acetylation of lysine residues of histones and other proteins is
one of the best known posttranslational modifications and is
performed by KATs (lysine acetyl transferases). The activity of these
enzymes relies on the availability of acetyl-CoA, an intermediary
metabolite produced mainly from b-oxidation of fatty acids and the
oxidative de-carboxylation of pyruvate by PDC (Lee & Workman,
2007; Etchegaray & Mostoslavsky, 2016). In nutrient-favorable
conditions, high acetyl-CoA levels trigger the regulation of specific
genes involved in growth and proliferation through histone acetyla-
tion, resulting in a more permissive chromatin configuration (Wel-
len et al, 2009; Cai et al, 2011). As described above, both acetyl-
CoA-producing pathways are reduced in sepsis with the oxidation of
fatty acids being downregulated and pyruvate being shuttled toward
aerobic glycolysis for the production of lactate. As a consequence, it
is possible that less acetyl-CoA is available for acetylation of
proteins which could explain the reduction in permissive histone
modifications observed by Bomsztyk et al (2015). Interestingly, a
clear link between the reduction in FFA oxidation, consequent low
acetyl-CoA levels, and low expression of neovascular genes by
suboptimal histone acetylation has been shown in mouse models in
the recent past (Schoors et al, 2015).
Histone deacetylases in sepsis
Another group of enzymes, involved in the removal of acetylation
groups, histone deacetylases (HDACs), might be of interest during
the pathology of sepsis. Several histone deacetylase inhibitors
(HDACi) have been tested as negative regulators of the expression of
important immune receptors and antimicrobial pathways in immune
cells. It was shown in multiple studies that HDACi can improve the
outcome after septic shock by reducing the cytokine storm, con-
firming the hypothesis that these inhibitors have potential as sepsis
therapeutics (Li et al, 2009; Zhang et al, 2010; Roger et al, 2011).
However, broad HDACi have also been associated with impaired
bacterial clearance and a more recent study suggested that specific
HDAC6 inhibition might improve responses during sepsis, while
preserving important microbicidal actions (Zhao et al, 2014). The
catalytic activity of SIRT6, a member of the class III HDACs, was
shown to be increased by certain FFAs up to 35-fold in vitro (Feld-
man et al, 2013). It has been hypothesized that in nutrient conditions
where FFAs are increased, SIRT6 activity could repress the transcrip-
tion of HIF-1a driven glycolytic genes by removing permissive acety-
lated histone marks (Zhong et al, 2010). During serious infections
where the increase in lipolysis causes FFAs levels to rise, this mecha-
nism could contribute to the reduction in histone acetylation and
alter the glucose metabolism. On the other hand, SIRT6 acts as a
tumor suppressor in cancer cells by inhibition of aerobic glycolysis
(Zhong et al, 2010; Sebastia´n et al, 2012). This raises the question
whether SIRT6 activation could also have potential as a druggable
target during severe acute inflammatory conditions.
Another SIRT enzyme that provides a link between metabolism
and inflammation is SIRT1. This deacetylase is activated by AMPK,
a crucial metabolic sensor that is activated under conditions of
elevated energy demand characterized by an increase in the AMP/
ATP ratio (Lan et al, 2008). SIRT1 has been shown to directly inter-
act with and deacetylate PGC-1a, as discussed above, a potent co-
factor of many transcription factors involved in energy expenditure
such as GR, PPAR-a, and PPAR-c, thereby enhancing their transcrip-
tional activity (Vega et al, 2000; Rodgers et al, 2005). Pharmacologi-
cal activation of SIRT1 shows potential for the treatment of sepsis
since PGC-1a expression was found to be severely downregulated in
muscle of septic mice, while SIRT1 activation proved to increase
survival in the CLP sepsis model (Rocheteau et al, 2015; Opal et al,
2016). Whether this reduction in mortality is caused in part by
improved PGC-1a transcriptional activity is still unexplored.
It is clear that the impaired energy metabolism in sepsis can
drive many epigenetic changes that could exacerbate the dysfunc-
tion of inflammatory and metabolic pathways. With more extensive
research into the variable epigenetics during sepsis and the possible
consequences, we could be paving the way to a new kind of drugs
for care of septic patients.
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Conclusion
In a healthy organism, energy expenditure and energy income are in
balance. During extensive exercise, the consumption of O2 by the
TCA cycle exceeds the available amounts, and the resulting hypoxia
leads to a mainly HIF-1a coordinated closure of the mitochondrial
import of pyruvate, and an increased production of lactate, which
can be consumed elsewhere in the body. The toxic lactate causes
muscle cramps, enforcing the end of the exercise. During starvation,
that is, when no or limited amounts of food enters the system, a
prolonged imbalance of the energy homeostasis is created and in
essence two systems are initiated to cause rearrangements of the
metabolism. First, hormones (glucagon, epinephrine, nore-
pinephrine, glucocorticoids), sensing low metabolic concentrations,
coordinate a starvation response, leading to the release of energy-
rich molecules from the resources, for example, glucose from glyco-
gen, AAs from protein and FFAs and glycerol from TGs. The AAs
will lead to glucose via gluconeogenesis in the liver, a process
strongly coordinated by glucocorticoids and the GR, while several of
the FFAs act as ligands for another nuclear receptor PPAR-a. These
receptors are transcription factors and induce genes that are essen-
tial in the gluconeogenesis and b-oxidation processes, respectively.
This is a system of high efficiency and strongly stimulated by the
transcriptional co-factor PGC1-a. Second, the amounts of mitochon-
dria, well-known as the organelles where TCA cycle and FFA b-
oxidation occur, are increased by a process of mitochondrial biogen-
esis, again by the stimulating action of PGC1-a.
In sepsis, the energy balance is clearly disturbed. There is energy
needed, but patients are unwilling or incapable to eat and a starva-
tion response develops. Due to the infection, an inflammation and
immune response develop, and as a consequence a HIF-1a signature
is seen (Fig 6). This leads to a limited mitochondrial function, which
may serve several goals. First, inflammation leads to mitochondrial
damage, so limiting the importance of these organelles in ATP
production seems logical. Second, the metabolism of glucose shifts
to aerobic glycolysis, which may be of interest for a more efficient
function of white blood cells. Third, some authors suggest that the
reduction in mitochondrial respiration under such conditions is a
conserved pathway of limiting energy expenditure, leading to a meta-
bolic reprogramming, as is observed during hibernation in several
mammalian taxa. Of course, neither humans nor mice are hibernating
species, so the importance of these pathways may be questioned.
Nevertheless, the danger of a reduced mitochondrial activity is obvi-
ous: Most of the energy-rich molecules produced from the energy
stores need active mitochondria to be properly consumed by cells. It
is likely that the systemic aspect of sepsis forms the major hurdle of
this strategy, because mitochondrial function in sepsis seems to be
failing in all tissues, and as a consequence, lactate, FFAs, and other
catabolic products accumulate and cause tissue damage and death.
Although it is clear that there is very significant metabolic repro-
gramming in sepsis, besides the activation of other complex systems
(inflammation, coagulation, complement activation, hypoxia
response), and given the fact that these pathways all influence one
another, it is hard to conclude how, where, and when the metabolic
pathways that are calling for therapeutic modulation have to be
addressed in a safe and effective way. Based on this overview of the
literature, it is our opinion that three early pathways deserve special
attention, namely (i) the generation of lactate by the increased HIF-
stimulated glycolysis, (ii) the accumulation of free fatty acids in the
blood, by the decreased ability of tissues to oxidize them via beta-
oxidation, and (iii) the decreased generation of ketone bodies by the
liver. Since the liver also appears to be undergoing these metabolic
rearrangements, and based on the availability of liver-targeting
approaches in today’s pharmacology, this organ could be the best
option to study in preclinical models of sepsis.
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Figure 6. The toxic consequences of metabolic reprogramming in sepsis.
Infection is the start of sepsis. It leads to direct tissue damage and to
inflammation, which in turn leads to hypoxia, which is essential to allow white
blood cells (WBCs) to produce fast ATP from glucose and act fast on the
infectious agents. The hypoxic response also leads to mobilization of energy-rich
molecules such as lactate and fatty acids, which however can also lead to
toxicity, when over abundant.
Pending issues
(i) Failure of all clinical sepsis trials is likely caused due to patient
heterogeneity: stratification is the key.
(ii) Studies directed toward the ideal sepsis animal model.
(iii) Studies elucidating sepsis as an inflammatory versus metabolic
disorder and identification of key target organs.
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